Ben Dowsing

BHF clinical training research fellow, utilising advanced cardiac imaging in cancer survivorship. HER-SAFE study:

[ESC Council of Cardio-Oncology Chairperson @ESCardioOnco]

🚨 Two randomized #CardioOncology trials at #ESCCongress2026!
🫀 RADICAL PC2: CV referral improved risk-factor control in prostate cancer.
💗 HER-SAFE: HF therapy withdrawal after recovery from anti-HER2 CTRCD appeared safe at 12 months.
@escardio @ESC_Journals

[Charlotte Manisty @dr_manisty]

Heart function stayed stable at 1 year after carefully monitored withdrawal of heart failure therapy in breast cancer survivors with recovered anti-HER2 cardiotoxicity. Work from our group at @ucl, presented by @bmdwsg as a Late-Breaking Trial at #ESCCongress 2026 & published simultaneously in @ehj_ed: HER-SAFE. @TheBHF @escardio @MycardiumAI #CardioOnc
🔗 https://t.co/pZ2m3aRnIp

[Maria Sol Andres MD, MSc 🇦🇷🇬🇧 @MariaSolAndres1]

Today Dr Ben Dowsing @bmdwsg presented the #HERSAFE trial. Can we safely stop CV medication after cancer treatment? All the answers in this #EHJ publication! https://t.co/sfbPMA3EKH @sohaibnazir @dr_manisty @arjunkg @ehj_ed

[Thomas Treibel @ThomasTreibel]

Excited to see our work on myocardial fibrosis and reverse remodelling after AVR for chronic aortic regurgitation published in @JAMACardio! https://t.co/8TwXiyKces
At 7 months post AVR:
🔹 LVEDV ↓44%
🔹 LV mass ↓21%
🔹 Matrix ↓15%
But focal scar did not regress #whyCMR @TheBHF

[Hunain Shiwani @HunainShiwani]

Glad to see our paper published in the European Heart Journal: Cardiovascular Imaging @ESC_Journals!

In 5,675 Cardiac MRI studies, asymmetrical septal hypertrophy (ASH) was present in 61% of hypertrophic cardiomyopathy (HCM) patients, but also 37% of ATTR amyloidosis, 26% of aortic stenosis and 23% of AL amyloidosis.

After accounting for age, sex & body size, however, excess asymmetry remained uniquely associated with HCM (ΔSLR +0.27).

https://t.co/2xiIv1ncWk

[Ben Dowsing @bmdwsg]

@MariaSolAndres1 @ucl Congratulations!

[Ben Dowsing @bmdwsg]

@HanCardiomd @ShelleyZieroth @hvanspall @DrMarthaGulati @BiykemB @biljana_parapid Reassuring that heart failure therapies appear to be effective in all, but remains important to tackle cardiovascular health inequalities. Women and patients with cancer often overlooked despite their CV risk.

(prior link is to a different work): https://t.co/r821xRNDiU

[Ben Dowsing @bmdwsg]

@mrcunitgambia @radboudumc @ChariteBerlin @AnjaSaso @UmbertoDAlessa2 @EdClarkeVaccine @UKRI_News @LSHTM @MohGambia @MRC_Uganda @The_MRC @WHO Amazing work by the brilliant @AnjaSaso and team!

[MRC Unit The Gambia at LSHTM @mrcunitgambia]

#PublicationAlert 🚨

A study led by @mrcunitgambia in partnership with @radboudumc and @ChariteBerlin, shows that vaccinating #PregnantWomen against #WhoopingCough protects babies in their blood and nasal lining, where infection starts.

Read more 👉 https://t.co/g5CpQtwwql

[International Cardio-Oncology Society @ICOSociety]

📞 Calling all Imaging Experts - we need your help. Please fill out this survey to help us understand your successes and challenges in cardiac imaging for cancer patients.

Link: https://t.co/rBRIo0ZBo3

#cardioonc #cardiacimaging #cardiooncology #cardiology #oncology #cancertreatment

[Ben Dowsing @bmdwsg]

@drbennisahmed Important question of remission vs recovery in HFimpEF. TRED-HF still doing the heavy lifting! HER-SAFE and STOP-MED CTRCD will provide more evidence in cancer survivors with improved CTRCD soon.
https://t.co/bbBs1qKvpu
https://t.co/XaAJ5jDD0S

[Ben Dowsing @bmdwsg]

@MariaSolAndres1 Congrats!

[Ben Dowsing @bmdwsg]

@CircAHA @bocchi @MBittencourtMD @monicaAGrinberg @lukadalech Great to see more evidence on protecting heart health whilst safely delivering vital cancer therapies. Though is relative GLS change precise enough to justify ARNI? LVEF remains in the normal range Tx or not. Can patients accept the burden of extra meds if no significant effect?

[Ben Dowsing @bmdwsg]

HER-SAFE study protocol: https://t.co/oiCena7och

[Ben Dowsing @bmdwsg]

Fantastic summary. Clinicians often underestimate the impact of lifelong poly pharmacy - “you say treatment, I say hard work!”. HER-SAFE will address GDMT withdrawal in breast cancer survivors with HFimpEF following antiHER cardiac dysfunction. Recruitment finishing soon!

[JACC Journals @JACCJournals]

In #JACCHF, Drs. Nandan Kodur & @WilsonTangMD review management of #HFimpEF
🔸Who must continue #GDMT?
🔸What are characteristics of those who may be able to withdraw?
🔸Where are the evidence gaps?
🔸What are areas for future study

🔗: https://t.co/7hxUuMUgZe

[JACC Journals @JACCJournals]

In #JACCHF, Drs. Nandan Kodur & @WilsonTangMD review management of #HFimpEF
🔸Who must continue #GDMT?
🔸What are characteristics of those who may be able to withdraw?
🔸Where are the evidence gaps?
🔸What are areas for future study

🔗: https://t.co/7hxUuMUgZe

[Ben Dowsing @bmdwsg]

@ChengshengJ @JACCJournals Congratulations! Well done. Vital work to help tackle the health inequalities faced by cancer patients with cardiovascular disease.

[Ben Dowsing @bmdwsg]

@HunainShiwani @JACCJournals Congratulations!

[Li Wei @LiWeiUCL]

A great collaboration between UCL, University of Dundee and HKU. Congratulations to @VincentKCYan @ChengshengJ Tom MacDonald, Isla Mackenzie, Rob Flynn, Bryan Williams, Yang Chen, Esther Chan, Jacob George & Li Wei for the publication of indapamide study https://t.co/BRdeeYDJqr

[Ben Dowsing @bmdwsg]

@MariaSolAndres1 @dr_manisty @sohaibnazir @arjunkg @RBandH A huge thanks to @MariaSolAndres1 and everyone working so hard to make HER-SAFE a success! Looking forward to providing some high quality evidence in this uncertain area of breast cancer survivorship. @TheBHF @UCL_ICS @NHSBartsHealth @uclh @RBandH @ImperialNHS